<DOC>
	<DOCNO>NCT01696500</DOCNO>
	<brief_summary>Patients diagnose Stevens-Johnson syndrome Toxic Epidermal Necrolysis confirm base investigator national diagnostic criterion . Patients meet inclusion criterion conflict exclusion criterion receive NPB-01 ( intravenous immunoglobulin ) 400mg/kg/day five consecutive day . Subsequently , efficacy NPB-01 therapy Stevens-Johnson syndrome Toxic Epidermal Necrolysis evaluate disease evaluation score et al . As safety endpoint , safety NPB-01 investigate occurrence adverse event 20 day start study treatment .</brief_summary>
	<brief_title>Phase III Clinical Trial NPB-01 Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive Corticosteroids .</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Stevens-Johnson Syndrome</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Patients disease evaluation score 14 study medication receive . 2 . Patients corticosteroid 20mg/day ( Prednisolone ) study medication receive continued treatment 2 day . 3 . Patients treatment effect insufficiency study medication receive need additional treatment . 4 . Patients age twenty year old informed consent . 1 . Patients SCORTEN score 4 study medication receive . 2 . Patients multiple organ failure study medication receive . 3 . Patients severe respiratory disorder study medication receive . 4 . Patients Druginduced hypersensitivity syndrome ( DIHS ) inform consent . 5 . Patients malignancy treatment informed consent . 6 . Patients treat corticosteroids dosage change 2 day study medication receive . 7 . Patients treat corticosteroid pulse therapy ( include semipulse therapy ) 2 day study medication receive . 8 . Patients treat plasmapheresis 2 day study medication receive . 9 . Patients treat highdose intravenous immunoglobulin 28 day inform consent . 10 . Patients history shock hypersensitivity NPB01 . 11 . Patients IgA deficiency . 12 . Patients severe impaired liver function diagnose virus hepatitis cirrhosis et al . 13 . Patients 2mg/dL serum creatinine . 14 . Patients severe cerebro cardiovascular disorder . 15 . Patients high risk thromboembolism . 16 . Patients hemolytic/hemorrhagic anemia . 17 . Patients severe decreased cardiac function . 18 . Patients decrease platelet less 75,000/Î¼L..</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>IVIG Stevens-Johnson syndrome</keyword>
	<keyword>Toxic Epidermal Necrolysis</keyword>
	<keyword>Patients Stevens-Johnson syndrome</keyword>
	<keyword>Toxic Epidermal Necrolysis unresponsive corticosteroid</keyword>
</DOC>